chrisvoncsefalvay/vaers-outcomes huggingface dataset:
I received the injection in my left hip.  I got COVID arm again, but smaller and shorter duration than the 1st.  Fever went over 104.  I started taking Tylenol.  The pain in my joints was excruciating this time.  I couldn?t hold a coffee mug without using both hands.  It was difficult to dress.  Shoulders hurt so much I had trouble sleeping.  All joints in hips, knees, ankles and feet hurt just as much.  It felt like my ankles and feet were broken.  I usually have a very high pain tolerance.  It felt like after the Neulasta shots after my chemotherapy treatments.  The bad part is I?m almost 5 weeks out and my fingers still feel broken .  The other joints got better after 3 weeks.  My finger joints are better, but it?s still painful.
a little bit redder in her legs; full body rash; This spontaneous case was reported by a consumer and describes the occurrence of ERYTHEMA (a little bit redder in her legs) and RASH (full body rash) in an 89-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 008B21A) for COVID-19 vaccination.     Concurrent medical conditions included Glaucoma and Blood pressure.    On 25-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced ERYTHEMA (a little bit redder in her legs) and RASH (full body rash). At the time of the report, ERYTHEMA (a little bit redder in her legs) and RASH (full body rash) had not resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Concomitant medications include medications for glaucoma, high blood pressure, irregular heart beat  Treatment include lotion on the rash.
received vaccine on 17Dec2020, then tested positive for coronavirus on 25Dec2020; received vaccine on 17Dec2020, then tested positive for coronavirus on 25Dec2020; This is a spontaneous report from a contactable nurse (patient). A female patient of an unspecified age received the first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE) via an unspecified route of administration on 17Dec2020 at a single dose for COVID-19 immunization. The patient's medical history and concomitant medications were not reported. The patient received vaccine on 17Dec2020, then tested positive for coronavirus on 25Dec2020. The patient was calling to inquire if she can get second vaccine. Outcome of the event was unknown.  Information on the lot/batch number has been requested.; Sender's Comments: Based on the current available information and the plausible drug-event temporal association, a possible contributory role of the suspect product BNT162B2 to the development of events Drug ineffective and COVID-19 cannot be totally excluded.  The case will be reassessed if additional information becomes available.
COVID 19 Treatment; COVID 19 Treatment; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 58-year-old female patient (not pregnant) received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), on 13Nov2022 as dose 5 (booster), single (Lot number: GH9694), in right arm for covid-19 immunisation; coviD-19 vaccine (COVID-19 VACCINE), as dose 1, single (Batch/Lot number: unknown), as dose 2, single (Batch/Lot number: unknown), as dose 3 (booster), single (Batch/Lot number: unknown) and as dose 4 (booster), single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history included: "non-Hodgkins lymphoma" (unspecified if ongoing), notes: In remission. The patient took concomitant medications. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant), outcome "recovering" and all described as "COVID 19 Treatment". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: Negative, notes: followed by 3 days testing negative (at-home test); Negative, notes: followed by 3 days testing negative (at-home test); Negative, notes: followed by 3 days testing negative (at-home test). Therapeutic measures were taken as a result of drug ineffective, covid-19.  Clinical information: Patient received Other medication in 2weeks, Patient received Paxlovid Treatment from16Apr2023 to 20Apr2023 for COVID-19.  No follow-up attempts are possible. No further information is expected.
Within a few hours of injection, pt developed a 50 cent piece size area of inflammation. Two days later, it had progressed to 4
60-year-old female with past medical history of heart 50 year, depression, diabetes, hypothyroidism, transaminitis, end-stage renal disease presents to the emergency department with generalized weakness.  Patient is a permanent resident at facility.  She receives hemodialysis on Tuesday, Thursday, Saturday.  Recently admitted to this facility in December.  Was found to have severe bradycardia likely secondary to her hyperkalemia.  Presented to ED 1/10/22; tested positive 1/10/22. T: 100.0 °F  TMIN: 100.0 °F  TMAX: 100.2 °F  HR: 89  RR: 16  BP: 142/118  SpO2: 95%  WT: 150 kg  BMI: 55.1   R Chest 1V [Auth (Verified)] (01/10 1541): FINAL IMPRESSION: Diffuse right lung airspace opacity is suggested XR Chest 01/10/22: FINAL IMPRESSION: Diffuse right lung airspace opacity is suggested with possible interstitial and airspace opacities also noted in the left mid and lower lung which may reflect multifocal pneumonia. Asymmetric pulmonary edema could have a similar appearance.Prominent cardiac silhouette
itches; Rash; red; This spontaneous case was reported by a consumer and describes the occurrence of PRURITUS (itches), RASH (Rash) and ERYTHEMA (red) in a 74-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 029L20A and 029L20A) for COVID-19 vaccination.     No medical history was provided by reporter.    On 17-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 14-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced PRURITUS (itches), RASH (Rash) and ERYTHEMA (red). At the time of the report, PRURITUS (itches), RASH (Rash) and ERYTHEMA (red) outcome was unknown.
Pt recv vax on 4/1/99; on 4/3/99 pt exp swollen arm x 24 hr
Patient diagnosed with COVI-19 with in 24 hours of receiving first vaccine dose. Patient is hospitalized and in critical care.
(R) arm - 6cm x 4cm raised, indurated, warm area. (L) 3-4 1cm Indurated areas no systemic effects.
Injection site swelled up the size of an egg. I could not move my arm for two days.
This spontaneous report as received from a registered nurse refers to a patient of unknown age and gender. The patient's concurrent conditions, pertinent medical history and concomitant therapies were not reported. Between 03-SEP-2017 and 11-SEP-2017, the patient was vaccinated with an improperly stored dose of VAQTA (lot # N005796, expiration date 26-MAY-2018) (dose and route were not reported) for prophylaxis. The vaccine was exposed to 8.5 Celsius degrees (°C) for 1 hour. There was no previous temperature excursion and also there was no "data logger". No adverse effects were reported. This is one of several reports from the same reporter. Sender's Comments: US-009507513-1709USA009437: US-009507513-1709USA009443: US-009507513-1709USA009439: US-009507513-1709USA009440: US-009507513-1709USA009441: US-009507513-1709USA009442: US-009507513-1709USA009436: US-009507513-1709USA009435: US-009507513-1709USA005606.
Severe pain at injection site for over 3 weeks. Swelling and very hot at injection site for 2 days with mottled red and white skin around the area. Discoloration, green/blue at injection site for 3 weeks. General malaise and joint discomfort. Difficulty raising arm.
Dizziness, nausea, dilated pupils, cold sweat. EMS called and released.
I received the vaccine Dec. 28th, 2020 in my left deltoid. There were no issues until January 5, 2021 in the evening when my arm started to itch. There was increased erythema, mild edema, and urticaria. The area is still red and itchy and while the erythema has increased outside the marked area on my deltoid, it has diminished in how vibrant it is.
headache; This spontaneous case was reported by a consumer and describes the occurrence of HEADACHE (headache) in a 70-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   On 14-Sep-2021, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient experienced HEADACHE (headache). At the time of the report, HEADACHE (headache) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Concomitant medications was not provided by the reporter  Treatment information was not provided.  It was reported that patient was asking if she can take Tylenol to treat a Headache after the third dose of her Moderna Covid-19 vaccine.   This case was linked to MOD-2021-321418, MOD-2021-321402 (Patient Link).
BODY ACHE; CHILLS; FEVER; HEADACHE; NAUSEA; This spontaneous report received from a patient concerned a 58 year old female. The patient's weight, height, and medical history were not reported. The patient received covid-19 vaccine (suspension for injection, route of admin not reported, batch number: 204A21A, expiry: UNKNOWN) dose was not reported, administered on 02-MAY-2021 for prophylactic vaccination. No concomitant medications were reported. On MAY-2021, the subject experienced body ache. On MAY-2021, the subject experienced chills. On MAY-2021, the subject experienced fever. On MAY-2021, the subject experienced headache. On MAY-2021, the subject experienced nausea. The action taken with covid-19 vaccine  was not applicable. The outcome of the fever, chills, headache, body ache and nausea was not reported. This report was non-serious.
Client's mother reports that when they arrived home, client "passed out" in back seat of car. This was about "10 minutes after the shot was administered. She was unresponsive for about 30 seconds 9or so). Mom says that client started "shaking" and she thought client was going into a seizure, but "she did not." The mother went to her immediately, taking to her and pulled her up from the lying position. Client then was responsive. They live close to a EMS worker who came and checked her vital signs - mom states they were fine. Also, after the client 'came to' she complained of a headache and difficulty breathing. Mom had her lie down to rest for awhile. During this time she again complained of difficulty which lasted only a few seconds, then she again felt fine. The remainder of the day, client had no symptoms and even went to facility a few hours later. We were notified of this incident on 8/23/07. The client was not seen by a medical professional. When the client was at the clinic for her shots, she was very nervous/anxious and was crying while the shots were being given.
Rt. arm red, hot, edematous, painful. Went to PCP, placed on oral and topical antibiotics x 10 days. Symptoms resolving after 9 days, has bruised area and knot in area now.
Hospital ER then admitted for right Pon?s Stroke, then transferred for rehab then discharged to home for rehab at outpatient therapy.  Continuing therapy now.
Initially, I noticed injection was given very high on the left shoulder. Upon injection, my left arm had an involuntary reflexive jerk, leading me to believe a nerve/ligament/tendon was hit. In the days to follow, I had typical muscle soreness like any other flu shot. Since then, I have been experiencing a deeper ache to sharp pain in my shoulder joint, to elbow, and down to my wrist. This has woken me up several nights up to today's date. I contacted my VA primary care team nurse on 10/13/2020 regarding the issue. Physical Therapy was ordered by my VA doctor. I received a phone call from VA Physical Therapy on 10/15/2020. via telephone video conference to start the physical therapy intake. My first appointment with Physical Therapy will be some time during the week of 10/19/2020.
Lightheadedness, dizziness immediately following injection lasting about 5-7 minutes; This is a spontaneous report from a contactable consumer, the patient. A 52-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8731) via an unspecified route of administration in the left arm on 14Apr2021 at 09:00 (at the age of 52-years-old) as a single dose for COVID-19 immunisation. Medical history included cough variant asthma. Patient had no known allergies. Concomitant medications included rosuvastatin calcium (CRESTOR) 5 mg, ascorbic acid (VITAMIN C), vitamin d nos (VITAMIN D) all from an unknown date for an unspecified indication. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 14Apr2021 at 09:00, the patient experienced light headedness, dizziness immediately following injection lasting about 5-7 minutes. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the events. The clinical outcome of events light headedness, dizziness immediately following injection lasting about 5-7 minutes was recovered on an unspecified date in Apr2021.   No follow-up attempts are needed. No further information is expected.
Information has been received from a 17 year old female patient with drug allergy to DIFLUCAN and LORABID and amoxicillin allergy and with no pertinent medical history, for HPV rL1 6 11 16 18, a Pregnancy Registry product, who on 15-MAY-2012 was vaccinated with a dose of HPV rL1 6 11 16 18 (lot # not reported). Secondary suspect therapy included a dose of hepatitis A virus vaccine inactivated (manufacturer unknown) (lot # not reported) at the same doctor visit. Concomitant therapy included a dose of meningococcal vaccine (unspecified) (lot # not reported) at the same doctor visit. On an unspecified date in May 2012, the patient took 5 pregnancy tests at home which showed that she was pregnant. Last menstrual period (LMP) was on 17-APR-2012 and the estimated delivery date (EDD) was on 22-JAN-2013. On 15-MAY-2012 the patient experienced injection sites hurt for a day or so, but the pain was "now: gone. The patient had sought medical attention by visiting the doctor. Follow-up was received from a registered nurse stating that the patient's hospital record stated that the baby appeared in good health. The last date that the patient had an appointment was in May 2012. The patient never came in to the office following birth. Additional information is not expected.
Gave Tdap shot then immediately after giving the flu shot the patient loss consciousness.  She turned very pale.  No seizure and still breathing.  She regained consciousness before paramedics arrived and no treatment was given.
Urticarial rash all over the body w/intense pruritus; Appeared about 3 hrs p/MMR/HIB given; Tx DPH;
The patient received dose from vial beyond 30-day use by date; This spontaneous case was reported by a health care professional and describes the occurrence of PRODUCT STORAGE ERROR (The patient received dose from vial beyond 30-day use by date) in a 50-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 037C21A) for COVID-19 vaccination.     No Medical History information was reported.    On 18-Jun-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 18-Jun-2021, the patient experienced PRODUCT STORAGE ERROR (The patient received dose from vial beyond 30-day use by date). On 18-Jun-2021, PRODUCT STORAGE ERROR (The patient received dose from vial beyond 30-day use by date) had resolved. Not Provided      For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   date of refrigeration is given as 7-May-2021, No concomitant and treatment medications are provided by the reporter.
"Half dollar size, hard swollen area" at injection site.  "Lasted a few days".
no adverse event; I've only taken one type of covid shot, Moderna vaccines. She has taken 2 doses on 17SEP2021 and 8DEC2022. This spontaneous case was reported by a patient and describes the occurrence of INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (I've only taken one type of covid shot, Moderna vaccines. She has taken 2 doses on 17SEP2021 and 8DEC2022.) and NO ADVERSE EVENT (no adverse event) in an adult female patient who received mRNA-1273 (Spikevax) for COVID-19 prophylaxis.     No Medical History information was reported.   On 17-Sep-2021, the patient received first dose of mRNA-1273 (Spikevax) (unknown route) 1 dosage form. On 08-Dec-2022, received second dose of mRNA-1273 (Spikevax) (unknown route) dosage was changed to 1 dosage form. On 08-Dec-2022, the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (I've only taken one type of covid shot, Moderna vaccines. She has taken 2 doses on 17SEP2021 and 8DEC2022.). On an unknown date, the patient experienced NO ADVERSE EVENT (no adverse event). At the time of the report, INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (I've only taken one type of covid shot, Moderna vaccines. She has taken 2 doses on 17SEP2021 and 8DEC2022.) and NO ADVERSE EVENT (no adverse event) outcome was unknown.        For mRNA-1273 (Spikevax) (Unknown), the reporter considered NO ADVERSE EVENT (no adverse event) to be not related. No further causality assessment was provided for INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (I've only taken one type of covid shot, Moderna vaccines. She has taken 2 doses on 17SEP2021 and 8DEC2022.).    No concomitant medication details was reported. No treatment medication details was reported.   Reporter did not allow further contact
Pt received expired flu vaccine consulted with district, state, CDC and manufacturer, revaccinated 10/05/06 no problems from expired vaccination.
pt has CTCL and has developed more intense itching than usual.  Pt has dementia but has had more severe episodes of aggression, confusion and delirium.  Her upper left arm is red and has developed more defined lesions around the injections site and on her lower back.  Her arm pain and back pain seemed to be heightened more than usual and she also has some fatigue. Pt saw her cancer Dr. on 3/24/21.  Dr. made notation in her chart about her symptoms and was instructed to continue the using the cream that she was currently using.  Pts PCP is aware of the increased episodes of confusion and being argumentative since taking the vax.  Pts daughter is her full time care giver and is dealing w/ her increased intensity of the patients symptoms.
they started to have and are ongoing ,sever hives, a rash and itchiness; they started to have and are ongoing ,sever hives, a rash and itchiness; they started to have and are ongoing ,sever hives, a rash and itchiness; Covid arm; This spontaneous case was reported by a consumer and describes the occurrence of URTICARIA (they started to have and are ongoing ,sever hives, a rash and itchiness), PRURITUS (they started to have and are ongoing ,sever hives, a rash and itchiness), VACCINATION SITE REACTION (Covid arm) and RASH (they started to have and are ongoing ,sever hives, a rash and itchiness) in a 71-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 011F21a, 0001a21a and 007b21a) for COVID-19 vaccination.     Concomitant products included TRAZODONE for an unknown indication.   On 24-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 24-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 27-Dec-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 29-Dec-2021,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced VACCINATION SITE REACTION (Covid arm). On 08-Jan-2022, the patient experienced URTICARIA (they started to have and are ongoing ,sever hives, a rash and itchiness), PRURITUS (they started to have and are ongoing ,sever hives, a rash and itchiness) and RASH (they started to have and are ongoing ,sever hives, a rash and itchiness). The patient was treated with LORATADINE, PSEUDOEPHEDRINE HYDROCHLORIDE (BENADRYL 24 D) at an unspecified dose and frequency and CETIRIZINE HYDROCHLORIDE (ZYRTEC ALLERGY) at an unspecified dose and frequency. On 31-Dec-2021, VACCINATION SITE REACTION (Covid arm) had resolved. At the time of the report, URTICARIA (they started to have and are ongoing ,sever hives, a rash and itchiness), PRURITUS (they started to have and are ongoing ,sever hives, a rash and itchiness) and RASH (they started to have and are ongoing ,sever hives, a rash and itchiness) had not resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Allergies (medications, food and other products) : NO Has patient ever had COVID + test or diagnosis?  NO No medical history was reported.   This case was linked to MOD-2022-477308, MOD-2022-477313 (Patient Link).
carpal tunnel left hand; pain at injection site; headache; chills; nausea; throwing up that night; This spontaneous case was reported by a consumer and describes the occurrence of CARPAL TUNNEL SYNDROME (carpal tunnel left hand), CHILLS (chills), NAUSEA (nausea), VOMITING (throwing up that night) and VACCINATION SITE PAIN (pain at injection site) in a 62-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 040B21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     Concurrent medical conditions included Sarcoidosis, Asthma, Carpal tunnel syndrome and Rotator cuff tear. Concomitant products included SALBUTAMOL (ALBUTEROL HFA) and VITAMINS NOS for an unknown indication.    On 08-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 10-Apr-2021, the patient experienced CHILLS (chills), NAUSEA (nausea) and VOMITING (throwing up that night). On an unknown date, the patient experienced CARPAL TUNNEL SYNDROME (carpal tunnel left hand), VACCINATION SITE PAIN (pain at injection site) and HEADACHE (headache). At the time of the report, CARPAL TUNNEL SYNDROME (carpal tunnel left hand), CHILLS (chills), NAUSEA (nausea) and VOMITING (throwing up that night) outcome was unknown and VACCINATION SITE PAIN (pain at injection site) and HEADACHE (headache) had resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Magnetic resonance imaging: abnormal (abnormal) Torn rotator cuff..     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown Route) was unknown.       Treatment medication was not provided.   Most recent FOLLOW-UP information incorporated above includes: On 22-Jul-2021: Followup received and contains information lab data MRI, reporter causality as not related.
Within 2 hr of vax pt devel generalized urticaria & erythema. Within next 12 hr pt devel fever. Tx w/Benadryl & acetaminophen. MD attributed event to Acel-Immune.